Mark Leo Spano

US Patent:

8447407, May 21, 2013

Filed:

Nov 1, 2010

Appl. No.:

12/917321

Inventors:

Sachin S. Talathi - Gainesville FL, US
Dong-Uk Hwang - Daejeon, KR
William L. Ditto - Scottsdale AZ, US
Paul R. Carney - Gainesville FL, US
Mark Spano - Scottsdale AZ, US

Assignee:

University of Florida Research Foundation, Inc. - Gainesville FL

International Classification:

A61N 1/3605

US Classification:

607 45, 600544, 600545

Abstract:

Neuronal excitation and inhibition of the brain is tracked in the hippocampal CA1 network during a latent period, wherein biomarkers are observed which include a sustained increase in the firing rate of the excitatory postsynaptic field activity, paired with a subsequent decrease in the firing rate of the inhibitory postsynaptic field activity; the mean amplitude profiles of both fEPSP and fEPSP field potential activity during the latent period have characteristic shapes; both excitatory and inhibitory CA1 field activity firing rates are observed to follow a circadian rhythm that drifts during epileptogenesis; the circadian rhythms described are in-phase in controls and anti-phase during epileptogenesis; and the fEPSP rate drifts from a circadian rhythm to a greater extent than the fEPSP rate. An additional biomarker is a change in a circadian rhythm of core body temperature. Therapeutic measures can include thermal, chemical, or electrical modulation, in an open or closed loop process.

US Patent:

20210223196, Jul 22, 2021

Filed:

May 4, 2018

Appl. No.:

16/612270

Inventors:

- Scottsdale AZ, US
- Rochester MN, US
Chi Lin - Tempe AZ, US
Mark Spano - Casa Grande AZ, US
Jennifer Blain Christen - Chandler AZ, US
Hongwu Jiang - Chandler AZ, US
Marcus Smith - Birmingham AL, US
Andrew Penman - Birmingham AL, US
Pierce Youngbar - Birmingham AL, US
Mackenzie Honikel - Chandler AZ, US
Curtiss Cook - Scottsdale AZ, US

International Classification:

G01N 27/02
G01N 27/327
G01N 33/487
G01N 27/22
G01N 35/00
G01N 33/569
G01N 33/66
G01N 33/53

Abstract:

The presence of analytes can be detected in the bodily fluid using Electrochemical Impedance Spectroscopy (EIS) or Electrochemical Capacitance Spectroscopy (ECS) in devices, such as handheld point-of-care devices. The devices, as well as systems and methods, utilize using Electrochemical Impedance Spectroscopy (EIS) or Electrochemical Capacitance Spectroscopy (EIS) in combination with an antibody or other target-capturing molecule on a working electrode. Imaginary impedance or phase shift, as well as background subtraction, also may be utilized.

US Patent:

20180232925, Aug 16, 2018

Filed:

Feb 9, 2018

Appl. No.:

15/893404

Inventors:

- Scottsdale AZ, US
Ross Maciejewski - Phoenix AZ, US
Mark Spano - Casa Grande AZ, US
Dustin Plaas - Gilbert AZ, US
Alison Van Putten - Phoenix AZ, US
Joseph Sansone - Phoenix AZ, US
Matthew Mortensen - Chandler AZ, US
Nathaniel Kirkpatrick - Atlanta GA, US
Jonah Thomas - Chandler AZ, US

International Classification:

G06T 11/60

Abstract:

Some systems include a memory, and a processor coupled to the memory, wherein the processor is configured to: identify one or more spatial markers in a medical data-based image of a patient, identify one or more spatial markers in a real-time perceived image of the patient, wherein the one or more spatial markers in the medical data-based image correspond to an anatomical feature of the patient and the one or more spatial markers in the real-time perceived image correspond to the anatomical feature of the patient, superimpose the medical data-based image of the patient with the real-time perceived image of the patient, and align the one or more spatial markers in the medical data-based image with the respective one or more spatial markers in the real-time perceived image.